Novartis Investigative Site

Gyeonggi-do, Korea 10408

1 studies enrolling now · 14 studies all time

What they study most

Advanced Metastatic Breast Cancer, Advanced, Metastatic Breast Cancer, Breast Cancer, Carcinoma, Non-Small-Cell Lung, Diffuse Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Early Breast Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer (NSCLC), Relapsing Forms of Multiple Sclerosis, Solid Tumors

Studies at this site

• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer — Recruiting now
• Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects — Stopped early
• A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer — Running, not enrolling
• Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer — Completed
• Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. — Completed
• Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) — Completed
• Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer — Completed
• Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors — Completed
• Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC — NO_LONGER_AVAILABLE
• A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi — Stopped early
• Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer — Completed
• Safety and Efficacy of BKM120 in Relapsed and Refractory NHL — Completed
• Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy — Completed